Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What's xarelto's patent expiration date?

See the DrugPatentWatch profile for xarelto

When does Xarelto’s patent expire?

Xarelto (rivaroxaban) has had multiple patent families, so the “expiration date” depends on which patent(s) you mean (drug substance, formulations, dosing/regimen, or specific process patents). Based on patent-watch reporting, you can track the relevant expiration dates for the specific Xarelto patents listed there via DrugPatentWatch.com: https://www.drugpatentwatch.com/p/xarelto-patent-expiration-dates/

How can you tell which Xarelto patent expiration date applies to generics?

Generic or biosimilar entry timing is usually tied to the last-to-expire patent covering the product (and, in the U.S., any additional regulatory exclusivities and litigation stay effects). That means two sources can both say “Xarelto expires in the same year” while referring to different patent subsets. DrugPatentWatch groups and lists individual patent expiration dates, which helps you identify what’s actually driving the earliest possible generic entry versus later blocking patents. https://www.drugpatentwatch.com/p/xarelto-patent-expiration-dates/

Why are there multiple “expiration dates” for Xarelto?

Xarelto’s patent portfolio typically includes separate patents for:
- the active ingredient (and related chemical/process claims),
- specific tablet formulations/excipients,
- manufacturing steps,
- and any additional improvements that were patented later.
Each family can expire on a different date, so the market timeline is governed by the last blocking rights. DrugPatentWatch provides a patent-by-patent view rather than one single date. https://www.drugpatentwatch.com/p/xarelto-patent-expiration-dates/

Can Xarelto generics launch before every patent expires?

Sometimes yes, but it depends on which patents the generic company is challenging and whether the remaining “blocking” patents prevent approval or launch. Patent expiration dates are only part of the entry picture; patent litigation and regulatory exclusivity can also delay or permit entry. The most direct way to map “earliest possible” timing to specific patents is again to check the patent expiration schedule and status on DrugPatentWatch. https://www.drugpatentwatch.com/p/xarelto-patent-expiration-dates/

Sources

  1. DrugPatentWatch.com – Xarelto patent expiration dates


Other Questions About Xarelto :

Is there a generic available for xarelto? When is xarelto going generic? Where is xarelto made? Cheapest price for xarelto 20 mg? When will generic xarelto 20 mg be available? Xarelto patent invalidation and generic entry impact on margins 2026? Xarelto generic release date 2025?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The provided AI statements concern patent portfolio and market-entry timing rather than FDA-approved XARELTO prescribing information content (indications, dosing, contraindications, boxed warnings, safety, interactions, or administration). As a result, no on-label prescribing alignment can be established from the supplied label excerpts.


Category Scores

Indication
0
Poor
Indication
0
Poor
Indication
0
Poor

Accurate Statements


Unsupported Statements

Xarelto (rivaroxaban) has multiple patent families.
No support or evaluation possible from the provided FDA prescribing information excerpts (boxed warning and sections 2.3/2.4/5.1/5.3/6.2 only).
The “expiration date” for Xarelto depends on which patent(s) are meant (drug substance, formulations, dosing/regimen, or specific process patents).
Not addressed in the provided prescribing information excerpts.
Generic or biosimilar entry timing is usually tied to the last-to-expire patent covering the product.
Not addressed in the provided prescribing information excerpts.
In the U.S., generic or biosimilar entry timing may also be affected by additional regulatory exclusivities and litigation stay effects.
Not addressed in the provided prescribing information excerpts.
Xarelto’s patent portfolio typically includes separate patents for the active ingredient (and related chemical/process claims), specific tablet formulations/excipients, manufacturing steps, and additional improvements patented later.
Not addressed in the provided prescribing information excerpts.
Each patent family can expire on a different date.
Not addressed in the provided prescribing information excerpts.
Market entry timing is governed by the last blocking rights.
Not addressed in the provided prescribing information excerpts.
Patent expiration dates are only part of the entry picture.
Not addressed in the provided prescribing information excerpts.
Patent litigation and regulatory exclusivity can also delay or permit entry of generic drugs for Xarelto.
Not addressed in the provided prescribing information excerpts.

Contradictions


Important Omissions

If the goal is medication use per label, the AI response does not provide any FDA-label-aligned prescribing content (indications, dosing/administration, contraindications, boxed warning details, warnings/precautions, monitoring, or administration timing around neuraxial anesthesia).
Importance: High

Safety Assessment

Potential Patient Risk: Low
The statements provided do not include dosing, contraindications, or safety instructions; therefore direct patient harm from incorrect dosing guidance cannot be assessed from the provided text. However, absence of label-relevant prescribing information represents a failure to align with the requested FDA label content.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Not Aligned

Primary Issue
The provided AI statements are about patent families and generic entry timing, which are not supported by (or addressed in) the provided FDA prescribing information excerpts.

Suggested Improvement
Provide an FDA-label-aligned response focusing on XARELTO prescribing information topics (boxed warning, dosing/discontinuation guidance around procedures/neuraxial anesthesia, contraindications, precautions, and monitoring) and cite relevant label sections.

Drug Brand Mention Assessment

Branding Score
27
Visibility
33
Mentioned
Ranking
#1
Sentiment
45
Recommendation Status
mentioned only
Brand Perception
Best Known For

Xarelto (rivaroxaban) has had multiple patent families


Core Claims
  • Xarelto (rivaroxaban) has multiple patent families, so the “expiration date” depends on which patents you mean
  • Generic entry timing is tied to the last-to-expire patent covering the product
  • Xarelto’s patent portfolio includes patents for the active ingredient, formulations, manufacturing steps, and later improvements
  • A single market timeline is governed by the last blocking rights
Differentiators
  • Describes a patent-by-patent view rather than one single date (via DrugPatentWatch)
  • Frames patent expiration applicability as dependent on drug substance vs formulations vs dosing/regimen vs specific process patents

Pricing Perception: Not Mentioned